14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
SENS vs VTAK: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
SENS Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 5–5 Matrix Metrics)
SENS Overall Winner
6-Pillar Tally: SENS 5 – 0 VTAK (1 Tie)
Matrix Metrics: SENS 5 – 5 VTAK
As of Nov 16, 2026, Senseonics Holdings, Inc. (SENS) is the stronger overall head-to-head candidate over Catheter Precision, Inc. (VTAK) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SENS carries a Unified Composite Score of 38.9/100 (SELL) at $10.90 (21.0x Forward P/E, -201.0% operating margin), whereas VTAK carries 58.1/100 (HOLD) at $0.15 (N/M Forward P/E, -388.1% operating margin).
Composite vs. Pillar Nuance: While VTAK currently prints a higher short-term Unified Composite Score (58.1/100 HOLD vs. SENS 38.9/100 SELL), SENS captures the overall institutional head-to-head verdict (5–5 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (-201.0% vs. -388.1% operating margin) and revenue trajectory (+141.6% vs. +380.7% YoY).
Technical & Structure Timing Caution: SENS trades in a Markup technical trend (CONSOLIDATION options phase, RSI 64.1); meanwhile VTAK is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Medical Devices value chain with $548,639 market capitalization and -388.1% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ SENS vs VTAK Key Questions & Quantitative Answers
As of Nov 16, 2026, Senseonics Holdings, Inc. (SENS) is the stronger overall head-to-head candidate over Catheter Precision, Inc. (VTAK) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SENS carries a Unified Composite Score of 38.9/100 (SELL) at $10.90 (21.0x Forward P/E, -201.0% operating margin), whereas VTAK carries 58.1/100 (HOLD) at $0.15 (N/M Forward P/E, -388.1% operating margin). Composite vs. Pillar Nuance: While VTAK currently prints a higher short-term Unified Composite Score (58.1/100 HOLD vs. SENS 38.9/100 SELL), SENS captures the overall institutional head-to-head verdict (5–5 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (-201.0% vs. -388.1% operating margin) and revenue trajectory (+141.6% vs. +380.7% YoY). Technical & Structure Timing Caution: SENS trades in a Markup technical trend (CONSOLIDATION options phase, RSI 64.1); meanwhile VTAK is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
SENS leads the Growth & Scale pillar: SENS posts +141.6% YoY revenue growth and +0.0% YoY earnings growth on $60M TTM revenue (58.7% gross margin, -201.0% operating margin), compared with VTAK at +380.7% YoY revenue growth and +0.0% YoY earnings growth on $1.9M TTM revenue (47.7% gross margin, -388.1% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), SENS cumulative revenue shifted +100.0% while VTAK shifted +0.0%. In operating R&D and SG&A reinvestment, SENS deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for VTAK.
SENS screens cheaper on headline valuation multiples. SENS trades at 21.0x Forward P/E, 21.0x Trailing P/E, N/M PEG, and 9.9x EV/Revenue (unreported FCF margin), whereas VTAK trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.3x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SENS (-157.3% ROE) versus VTAK (-111.3% ROE) capital efficiency.
In options market volatility and institutional positioning, SENS carries 68.8% implied volatility (35th %ile, Balanced (25th–60th %ile)), a 0.14x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.98β · 101% Vol realized risk). By comparison, VTAK carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.19β · 76% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.